Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Withdrawn Phase 2 Interventional

S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

ClinicalTrials.gov ID: NCT01055301

Public ClinicalTrials.gov record NCT01055301. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 3, 2026, 11:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

S0833, Modified Total Therapy 3 (TT3) for Newly Diagnosed Patients With Multiple Myeloma (MM): A Phase II SWOG Trial for Patients Aged ≤ 65 Years

Study identification

NCT ID
NCT01055301
Recruitment status
Withdrawn
Study type
Interventional
Phase
Phase 2
Lead sponsor
SWOG Cancer Research Network
Network
Enrollment
Not listed

Conditions and interventions

Interventions

  • autologous-autologous tandem hematopoietic stem cell transplantation Procedure
  • bortezomib Drug
  • cisplatin Drug
  • cyclophosphamide Drug
  • dexamethasone Drug
  • doxorubicin hydrochloride Drug
  • etoposide Drug
  • gene expression analysis Genetic
  • laboratory biomarker analysis Other
  • lenalidomide Drug
  • melphalan Drug
  • microarray analysis Genetic
  • thalidomide Drug

Procedure · Drug · Genetic + 1 more

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2011
Primary completion
Jun 30, 2011
Completion
Jun 30, 2011
Last update posted
Mar 5, 2015

2011

United States locations

U.S. sites
21
U.S. states
4
U.S. cities
15
Facility City State ZIP Site status
Tulane Cancer Center Office of Clinical Research Alexandria Louisiana 71315-3198
Hematology-Oncology Clinic Baton Rouge Louisiana 70809
Barbara Ann Karmanos Cancer Institute Detroit Michigan 48201-1379
University of Mississippi Cancer Clinic Jackson Mississippi 39216
Island Hospital Cancer Care Center at Island Hospital Anacortes Washington 98221
St. Joseph Cancer Center Bellingham Washington 98225
Olympic Hematology and Oncology Bremerton Washington 98310
Highline Medical Center Cancer Center Burien Washington 98166
Columbia Basin Hematology Kennewick Washington 99336
Skagit Valley Hospital Cancer Care Center Mount Vernon Washington 98274
Harrison Poulsbo Hematology and Onocology Poulsbo Washington 98370
Harborview Medical Center Seattle Washington 98104
Minor and James Medical, PLLC Seattle Washington 98104
Fred Hutchinson Cancer Research Center Seattle Washington 98109
Group Health Central Hospital Seattle Washington 98112
Swedish Cancer Institute at Swedish Medical Center - First Hill Campus Seattle Washington 98122-4307
University Cancer Center at University of Washington Medical Center Seattle Washington 98195
North Puget Oncology at United General Hospital Sedro-Woolley Washington 98284
Cancer Care Northwest - Spokane South Spokane Washington 99202
Evergreen Hematology and Oncology, PS Spokane Washington 99218
Wenatchee Valley Medical Center Wenatchee Washington 98801-2028

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01055301, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 5, 2015 · Synced May 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01055301 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →